Search In this Thesis
   Search In this Thesis  
العنوان
Comparative study between Red Cell Distribution Width and Creatine Kinase-MB as prognostic markers in Acute Coronary Syndrome \
المؤلف
Arfa, Mahmoud Ahmed Mahmoud.
هيئة الاعداد
باحث / محمود أحمد محمود عرفه
مشرف / نبيلة محمد عبد العزيز فهمي
مشرف / الفريد موريس سعيد بقطر
مشرف / ضياء الدين محمود هيبة
تاريخ النشر
2018.
عدد الصفحات
136 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
العناية المركزة والطب العناية المركزة
تاريخ الإجازة
1/1/2018
مكان الإجازة
جامعة عين شمس - كلية الطب - الرعاية المركزة
الفهرس
Only 14 pages are availabe for public view

from 136

from 136

Abstract

Red cell distribution width (RDW) is a measure of circulating erythrocyte size heterogeneity, it is obtained routinely from automated complete blood count (CBC), some investigations showed that RDW could be an important marker for cardiovascular diseases.
The present study aimed to investigate the relationship between red cell distribution width and the adverse clinical out-comes (in hospital course) in patients with acute coronary syndrome.
The present study was conducted on 60 patients referred to Ain Shams University with acute coronary syndrome at the period from June 2017 to July 2018.
All patients enrolled in the study fulfilled the mentioned inclusion criteria. They all were subjected to history taking and clinical examination upon admission, patient`s clinical characteristics such as age,sex,diabetes mellitus (DM), hypertension and smoking were recorded, standard 12-leads ECGs, were performed for all patients, and blood samples were taken for analysis of RDW using the automated hematology analyzer.
An informed consent was taken from all patients before enrollment in the study. Privacy of the participants and confidently of the data is preserved through identification of patient cooding system. Any unexpected risk appeared during the course of the study were being cleared to the participants and ethical committee on time.
The current study showed that after 12 hours of admission we found that when RDW level was from 10 to 15, two cases recorded with heart failure, two cases recorded with V-T and VF, three cases recorded with CHB, six cases recorded success of reperfusion and two cases recorded with Re-infarction, there was highly statistically significant difference between RDW and all Outcomes After 12 hours, when p-value was <0.001**
And when RDW level was >15, four cases recorded with heart failure, three cases recorded with mechanical complications (Mitral Regurge), two cases recorded with VT-VF, four cases recorded with success of reperfusion and four cases recorded with Re-infarction, there was highly statistically significant difference between RDW and all Outcomes After 12 hours, when p-value was <0.001**.
Also after 24 hours after admission results showed that when RDW level was >15, four cases recorded with mechanical complications (Mitral Regurge), when p-value was <0.05*.
And eventually after 48 hours after admission results showed that when RDW level was from 10 to 15, one case recorded with heart failure and one case recorded with Re-infarction, there was statistically significant difference between RDW and all Outcomes After 48 hours, when p-value was <0.05*..
And when RDW level was >15, five cases recorded with heart failure, four cases recorded with mechanical complications (Mitral Regurge), five cases recorded with VT-VF, three cases recorded with CHB and six cases recorded with Re-infarction, there was statistically significant difference between RDW and all Outcomes After 48 hours, when p-value was <0.05*.
The present study showed that adverse events were more likely to occur in patients with ACS during short-term follow up if they had higher RDW values. Logistic regression analysis revealed that RDW was an independent predictor for cardiac mortality, onset of heart failure and serious arrhythmia during hospital stay in patients with ACS. The research suggest that measuring the RDW level may provide valuable information for short-term stratification of ACS.
RDW is widely available to clinicians as part of complete blood count and therefore incurs no additional costs, in contrast to other markers of cardiovascular risk.